Design
Review
Key result
While the pipeline for new hypertension drugs is declining, novel approaches like neprilysin inhibition, PDE5 inhibition, and protective RAAS stimulation offer potential therapeutic avenues.
Authors
Loading...
May prompt trials of neprilysin/PDE5 inhibitors in resistant hypertension; leaves open clinical translation amid declining pipelines.
While the pipeline for new antihypertensive drugs is shrinking, targeting novel pathways like the protective RAAS and dual NEP inhibition provides a glimmer of hope for future therapies.
Paulis et al. (2015) conducted a review in Hypertension. Novel antihypertensive agents was evaluated. While the pipeline for new hypertension drugs is declining, novel approaches like neprilysin inhibition, PDE5 inhibition, and protective RAAS stimulation offer potential therapeutic avenues.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: